David A. Siegel Design Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 40,500 shares of DSGN stock, worth $298,485. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,500
Previous 108,500
62.67%
Holding current value
$298,485
Previous $365,000
16.71%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding DSGN
# of Institutions
98Shares Held
34.1MCall Options Held
0Put Options Held
0-
Sr One Capital Management, LP6.53MShares$48.1 Million11.31% of portfolio
-
Logos Global Management LP San Francisco, CA3.66MShares$26.9 Million3.19% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.34MShares$24.6 Million0.05% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$17 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.95MShares$14.4 Million0.62% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $411M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...